The psychosocial burden of psoriatic arthritis

https://doi.org/10.1016/j.semarthrit.2017.05.010Get rights and content
Under a Creative Commons license
open access

Abstract

Objective

To assess the psychosocial impact of psoriatic arthritis (PsA), describe how health-related quality of life (QoL) is affected in patients with PsA, discuss measures used to evaluate the psychosocial impact of PsA, and review studies examining the effect of therapy on QoL.

Methods

A targeted review on the impact of PsA on QoL and the role of tailored psychosocial management in reducing the psychosocial burden of the disease was performed. PubMed literature searches were conducted using the terms PsA, psychosocial burden, QoL, and mood/behavioral changes. Articles were deemed relevant if they presented information regarding the psychosocial impact of PsA, methods used to evaluate these impacts, or ways to manage/improve management of PsA and its resulting comorbidities. The findings of this literature search are descriptively reviewed and the authors׳ expert opinion on their interpretation is provided.

Results

The psychosocial burden of PsA negatively affects QoL. Patients suffer from sleep disorders, fatigue, low-level stress, depression and mood/behavioral changes, poor body image, and reduced work productivity. Additionally, each patient responds to pain differently, depending on a variety of psychological factors including personality structure, cognition, and attention to pain. Strategies for evaluating the burdens associated with PsA and the results of properly managing patients with PsA are described.

Conclusions

PsA is associated with a considerable psychosocial burden and new assessment tools, specific to PsA, have been developed to help quantify this burden in patients. Future management algorithms of PsA should incorporate appropriate assessment and management of psychological and physical concerns of patients. Furthermore, patients with PsA should be managed by a multidisciplinary team that works in coordination with the patient and their family or caregivers.

Keywords

Psoriatic arthritis
Psychosocial burden
Psychosocial assessment tools
Psoriatic arthritis management

Cited by (0)

M.E. Husni has consulted for AbbVie, Bristol-Myers Squibb, Pfizer, UCB, Novartis, Eli Lilly, Janssen, and Genentech.

J. Merola has served as an investigator for Amgen, Pfizer, and Biogen IDEC; has consulted for Biogen IDEC, Amgen, Eli Lilly, Janssen and Novartis; has served as a speaker for AbbVie.

S. Davin has no conflicts of interest.